MARKET

TLPH

TLPH

Talphera Inc
NASDAQ
1.310
-0.050
-3.68%
After Hours: 1.330 +0.02 +1.53% 19:45 03/01 EST
OPEN
1.450
PREV CLOSE
1.360
HIGH
1.450
LOW
1.310
VOLUME
61.08K
TURNOVER
0
52 WEEK HIGH
1.610
52 WEEK LOW
0.4250
MARKET CAP
22.21M
P/E (TTM)
-0.4512
1D
5D
1M
3M
1Y
5Y
Talphera Board Reshuffle and Nasdaq Compliance Triumph
TipRanks · 1d ago
Talphera reduces size of board from ten to seven members
Talphera reduces size of board from ten to seven members. Three directors, Howard Rosen, Richard Afable and Pamela Palmer have voluntarily agreed to resign from the Board of Directors. Talphera, Inc. (TLPH) Stock is down 1.7% to $7.50.
Seeking Alpha · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Check out the biggest pre-market stock movers for Thursday. Societal CDMO stock is rocketing more than 130% after announcing an acquisition agreement. Volcon shares are soaring over 109% alongside heavy pre- market trading. Biggest pre-Market Stock Movers: 10 Top Gainers and Top 10 Losers.
Investorplace · 2d ago
Talphera Inc: Statement of changes in beneficial ownership of securities
Press release · 4d ago
Weekly Report: what happened at TLPH last week (0219-0223)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Ocean Biomedical (NASDAQ:OCEA) stock rose 37.6% to $2.16 during Friday's after-market session. The company's market cap stands at $73.6 million. NeuBase Therapeutics and Virax Biolabs Group also moved upwards. Losers include Telesis Bio and Celularity.
Benzinga · 02/23 21:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Inspire Veterinary (NASDAQ:IVP) stock increased by 47.8% to $0.2 during Wednesday's pre-market session. Motus GI Hldgs shares rose 47.17% during the day. Talphera stock rose 18.39% and Ocugen increased by 15.38% in the pre- market session. Losers Avinger and Teladoc Health were among the companies that lost ground.
Benzinga · 02/21 13:06
Weekly Report: what happened at TLPH last week (0212-0216)?
Weekly Report · 02/19 12:36
More
About TLPH
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

Webull offers Talphera Inc stock information, including NASDAQ: TLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLPH stock methods without spending real money on the virtual paper trading platform.